New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05238883
First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 25 times
Summary
This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The main goal is to find a safe dose and check for side effects. About 72 participants will take part in two phases: first, increasing doses to find the best one, then testing that dose in specific cancer groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NEXT Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
The University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.